News center | United States​

September 15, 2017

Philips launches cardiac SPECT solution at the American Society of Nuclear Cardiology’s Annual Scientific Session

Amsterdam, The Netherlands and Kansas City, Mo. Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its presence at the American Society of Nuclear Cardiology’s Annual Scientific Session in Kansas City, Missouri, from September 14 – 17, 2017. At this year’s session, Philips is highlighting its newest solution for nuclear cardiology, CardioMD IV, a solution leveraging Single Photon Emission Computed Tomography (SPECT) technology, advanced Astonish reconstruction and cardiac quantification software to deliver diagnostic confidence and improved workflow for cardiac imaging. 


Recognizing molecular imaging’s unique ability to transform healthcare, CardioMD IV is tailored to address the most pressing challenges in cardiac imaging today. This dedicated cardiac SPECT solution was designed to fit the clinical and economic needs of healthcare institutions. With a small footprint, CardioMD IV will fit in virtually any existing camera room without requiring costly renovations. Its patient-friendly design allows for greater positioning flexibility, and half-time cardiac imaging with Astonish reconstruction improves workflow efficiency without sacrificing image quality. Philips’ advanced visualization and analysis platform, IntelliSpace Portal, provides enterprise-wide access to the latest cardiac SPECT quantification, review and reporting applications while enabling effective collaboration among cardiologists and referring physicians.


“Our aim is to advance molecular imaging in all disease areas, and provide dependable imaging solutions to enhance diagnostic confidence and patient care at lower costs,” said Kirill Shalyaev, Ph.D., Business Leader, Advanced Molecular Imaging, Philips Healthcare. “CardioMD IV delivers the reliable performance and the low total cost of ownership that nuclear cardiology practices need to drive clinical, financial and operational efficiencies.” 


Visit the Philips booth #412 for more information about CardioMD IV and Philips’ innovative solutions and services that provide physicians and hospitals the opportunity to deliver advanced cardiovascular care to patients.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at

Click here to read onClick here to read less



Alicia Cafardi

Alicia Cafardi

Philips Global Press Office

Tel: +1 412-523-9616

You are about to visit a Philips global content page


Share on social media

  • Link copied

You are about to visit a Philips global content page


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.